François Guilhot - Concepedia

Author

François Guilhot

Also Known As

Alessandro Consolaro, F Guilhot, F. Guilhot, Florence Guilhot, Francois Guilhot, Francoise Guilhot, Francosie Guilhot, Francçois Guilhot, François Guilhot, François Guilhot

625

Publications

42.6K

Citations

H-Index

123

Concepts

All Affiliations

Inserm Centre Hospitalier Universitaire de Poitiers Hôpital Saint-Louis Université de Poitiers The University of Texas MD Anderson Cancer Center

About

François Guilhot is an author at Inserm specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	80	7.1K
2	Health Sciences	23	38	4.7K
3	Engineering	3	3	96
4	Biochemistry	2	2	60
5	Natural Sciences	1	1	22

François Guilhot

237

Publications

34.3K

Citations

H-Index

Page 1

	Year	Citations
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Stephen G. O’Brien, François Guilhot, Richard A. Larson, New England Journal of Medicine	2003	3.5K
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Brian Druker, François Guilhot, Stephen G. O’Brien, New England Journal of Medicine	2006	3.5K
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus, New England Journal of Medicine	2002	2K
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot, The Lancet Oncology Hematological MalignancyOncologyChronic Myeloid LeukaemiaHematologyMyeloid Neoplasia	2010	1.5K
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Andreas Hochhaus, Richard A. Larson, François Guilhot, New England Journal of Medicine	2017	1.2K
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, New England Journal of Medicine	2013	1.1K
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma Michel Attal, Thierry Façon, François Guilhot, New England Journal of Medicine	2003	973
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Andreas Hochhaus, S G O'Brien, François Guilhot, Leukemia Hematological MalignancyChronic Myeloid LeukemiaMedicineHematologyMyeloid Neoplasia	2009	842
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Richard A. Larson, Brian Druker, François Guilhot, Blood	2008	631
International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Michael W. Deininger, Stephen G. O’Brien, François Guilhot, Blood	2009	615

Page 1